Ryplazim
Payments companies reported to CMS as associated with Ryplazim. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ryplazim, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ryplazim
These are the largest totals companies reported as associated with Ryplazim. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Gerami Seitzman | San Francisco, CA | Ophthalmology | $13,070.92 |
| Michael Tarantino | Peoria, IL | Pediatric Hematology-Oncology | $6,049.00 |
| Meera Chitlur | Detroit, MI | Pediatrics | $5,400.00 |
| Mark Reding | Minneapolis, MN | Hematology & Oncology | $4,200.00 |
| Amol Sura | San Francisco, CA | Ophthalmology | $4,000.00 |
| Angela Zhu | Miami, FL | Ophthalmology | $3,000.00 |
| Charles Nakar | Indianapolis, IN | Pediatric Hematology-Oncology | $1,200.00 |
| Melinda Chang | Los Angeles, CA | Ophthalmology | $136.24 |
| Angeline Nguyen | Stanford, CA | Ophthalmology | $136.24 |
| Allison Wang | Los Angeles, CA | Pediatrics (Nurse Practitioner) | $136.24 |
Prescribed Ryplazim?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.